Researchers have discovered a novel treatment to relieve cytokine release syndrome (CRS), a life-threatening inflammation triggered by a serious infection or severe burn. Treatment with a short-acting antibody reduces the inflammatory effects of interleukin-6, a key cytokine in CRS while avoiding the side effects associated with previous longer-acting therapies.